---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-050077"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:37:16.286927+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M

## Summary
- Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).
- Q4 net income $0.3M (vs $5.6M in Q4 2020); FY net income $4.4M (vs $19.4M in 2020).
- Adjusted EBITDA Q4 $5.5M; FY $17.5M, up from $15.4M in 2020.
- Installed base 1,110 instruments; 453 instrument placements in FY2021.
- FY2022 revenue guidance $160-168M, representing 25-31% growth over FY2021.

## SEC filing metadata
- accession: 0001193125-22-050077
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312522050077/0001193125-22-050077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312522050077/d305036d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-050077
- JSON: https://secwatch.observer/filing/0001193125-22-050077.json
- Plain text: https://secwatch.observer/filing/0001193125-22-050077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.